As we step into the new year, Ncardia is delighted to reflect on the transformative journey of 2023, marked by innovation, expansion, and strategic leadership. Throughout the year, we launched several initiatives aimed at advancing the use of induced pluripotent stem cells (iPSCs) to revolutionize drug discovery. Here are some key highlights that defined our remarkable year:
Expanding Capacities and Capabilities to Support Long-Term Partnership with Therapeutic Developers
New offices in Leiden, Netherlands
To accommodate our expanding team and meet the need for increased laboratory capacity, Ncardia successfully relocated to a spacious facility in Leiden, Netherlands. This strategic move not only accommodates our growing workforce but also equips us with state-of-the-art laboratories and updated equipment. This investment empowers us to undertake more extensive and comprehensive programs, reinforcing our commitment to cutting-edge internal innovations.
Strengthening Project Management
Recognizing the importance of efficient project execution, we bolstered our resources by establishing a dedicated project management team led by Astrid Norenberg. This team is driven by the goal of not only meeting but exceeding client expectations. By monitoring performance and shortening timelines, Ncardia is positioned to deliver results with unparalleled efficiency.
Introducing New Services
As part of our commitment to provide comprehensive solutions, we expanded our portfolio with the introduction of the Proteinopathy Exploration Package. This innovative package consists of three assays based on Ncardia's iPSC technology, specifically designed to offer a holistic evaluation of drug candidates targeting TAU, α-Syn, and TDP-43 aggregation simultaneously. Tailored for Alzheimer’s, Parkinson’s disease, and ALS research, this new service enhances our ability to assess drug efficacy in combating neurodegenerative diseases.
Strengthening the Leadership Team
-1.png?width=223&height=216&name=Ncardia%20Team%20Page%20(1)-1.png)
Welcoming Jeroen de Groot, PhD, as Divisional Chief Executive: Ncardia proudly welcomes Dr. Jeroen de Groot as our Divisional Chief Executive. With a distinguished background in leading international contract research organizations, Dr. de Groot brings extensive experience in innovation, drug discovery, and development. His leadership, shaped by previous roles including Chief Operating Officer Early Discovery at Charles River Laboratories, will undoubtedly contribute to Ncardia's ongoing success.
Vincent Mancuso Takes Charge as SVP Global Engineering and Operations Support: In a move to enhance operational excellence, Vincent Mancuso has joined Ncardia as Senior Vice President, Global Engineering and Operations Support. Focused on procurement, supply chain, environmental health and safety, and IT, Mancuso's role is pivotal to optimizing our operational functions.
Timothy Keefe Joins as SVP Business Development: Adding to our leadership strength, Timothy Keefe assumes the role of Senior Vice President, Business Development. With over a decade of experience in life sciences and biotechnology, Keefe's expertise in sales leadership and strategic management aligns seamlessly with Ncardia's vision for growth and collaboration.
Looking Ahead: Opportunities in 2024
Building on the successes of 2023, Ncardia is excited about the potential this year holds. We are committed to accelerating your programs by both diversifying our service offerings and enhancing our inventory of iPSC products. Moving forward, Ncardia will bring forth numerous additional updates, including the unveiling of our vision statement for 2024.
If you are looking for mutually beneficial partnerships that can help you push the boundaries of iPSC innovation to bring better therapies to patients faster, contact us today.